Based on antibody engineering technology, ITRI developed ITRI-501, an anti-TIGIT antibody drug for effectively blocking the interaction of TIGIT with cognate ligand, CD155 expressed on tumor cell, and then activated the cytotoxic T cells. Compared with the clinical drugs, ITRI-501 exhibited a superior efficacy on tumor cell killing by more than several times. It can be used as a single treatment or combined with other drugs for combinational therapy.

Features & Specifications:
・ITRI-501 can effectively block the binding of TIGIT with CD155 and has a superior capability to activate T cells than other anti-TIGIT antibodies.
・ITRI-501 is non-immunogenic and recognize an unite epitope of TIGIT, these features confer ITRI-501 patentability.
・ITRI-501 possesses a stronger antibody-dependent cell-mediated cytotoxicity (ADCC) against TIGIT-expressing regulatory T cell lines than other anti-TIGIT antibodies developed by competitors (BMS and Roche).
・2F1-LE6, a surrogate antibody of ITRI-501, has shown to have a superior curative effect in a syngeneic mouse colon tumor model (CT26 or MC38)
・In the human TIGIT gene knock-in mouse, monotherapy of ITRI-501 exhibited a promising activity in inhibiting the growth of MC38 colon cancer cells.